ImportRefusal LogoImportRefusal

Laboratorios Paill

⚠️ High Risk

FEI: 3010327213 • San Salvador, San Salvador • EL SALVADOR

FEI

FEI Number

3010327213

📍

Location

San Salvador, San Salvador

🇸🇻
🏢

Address

8a,Av sur y 10ac.Ote. # 470, , San Salvador, San Salvador, El Salvador

High Risk

FDA Import Risk Assessment

57.6
LowModerateHighCritical

This firm has a significant history of FDA import refusals with notable violations.

Statistics

9
Total Refusals
5
Unique Violations
1/22/2026
Latest Refusal
12/26/2012
Earliest Refusal

Score Breakdown

Violation Severity
65.6×40%
Refusal Volume
37.0×30%
Recency
98.1×20%
Frequency
6.9×10%
How is this score calculated?

Proprietary Algorithm

  • 40% Violation Severity — AI-assessed (1-10)
  • 30% Refusal Volume — Logarithmic scale
  • 20% Recency — Decays over 5 years
  • 10% Frequency — Refusals per year

© ImportRefusal.com Original Analysis

Violation Summary

758×

UNAPPROVED

The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA).

1184×

NOT LISTED

It appears the drug or device is not included in a list required by Section 510(j), or a notice or other information respecting it was not provided as required by section 510(j) or 510(k).

4723×

NO ENGLISH

Required label or labeling appears to not be in English in violation of 21 C.F.R. 201.15(c)(1).

32802×

FRNMFGREG

The article is subject to refusal of admission pursuant to section 801(a)(3) in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. It appears that it was manufactured, prepared, propagated, compounded, or processed in an establishment not duly registered under section 510 of the Act.

821×

RX LEGEND

The article appears to be a prescription drug without a prescription drug legend as required by Section 503(b)(4).

Refusal History

DateProductViolationsDivision
1/22/2026
62GDY18DICLOFENAC SODIUM (ANTI-INFLAMMATORY)
75UNAPPROVED
Division of Southeast Imports (DSEI)
4/12/2024
65QCC24ORPHENADRINE CITRATE (RELAXANT)
75UNAPPROVED
Division of Southeast Imports (DSEI)
2/15/2024
60SCC06BISMUTH (ANTACID)
118NOT LISTED
75UNAPPROVED
Division of Southeast Imports (DSEI)
12/9/2022
54AGY04VITAMIN B6 (PYRIDOXINE)
75UNAPPROVED
Division of Southeast Imports (DSEI)
7/11/2019
60LBK99ANALGESIC, N.E.C.
118NOT LISTED
3280FRNMFGREG
472NO ENGLISH
75UNAPPROVED
82RX LEGEND
Division of Southeast Imports (DSEI)
7/11/2019
62UAA99ANTI-TUSSIVE/COLD N.E.C.
118NOT LISTED
3280FRNMFGREG
472NO ENGLISH
75UNAPPROVED
Division of Southeast Imports (DSEI)
7/11/2019
62UBG99ANTI-TUSSIVE/COLD N.E.C.
472NO ENGLISH
Division of Southeast Imports (DSEI)
4/10/2014
66VDY99MISCELLANEOUS PATENT MEDICINES, ETC.
75UNAPPROVED
Division of Southeast Imports (DSEI)
12/26/2012
66VAA99MISCELLANEOUS PATENT MEDICINES, ETC.
118NOT LISTED
75UNAPPROVED
Florida District Office (FLA-DO)

Frequently Asked Questions

What is Laboratorios Paill's FDA import refusal history?

Laboratorios Paill (FEI: 3010327213) has 9 FDA import refusal record(s) in our database, spanning from 12/26/2012 to 1/22/2026.

What is an FEI number?

FEI stands for Firm Establishment Identifier. It's a unique number assigned by the FDA to identify establishments that manufacture, process, pack, or hold food, drugs, medical devices, or other FDA-regulated products. Laboratorios Paill's FEI number is 3010327213.

What types of violations has Laboratorios Paill received?

Laboratorios Paill has been cited for 5 different violation type(s). Common FDA violations include adulteration (unsafe or unsanitary products), misbranding (incorrect or misleading labels), and regulatory non-compliance.

Where does this information about Laboratorios Paill come from?

All FDA import refusal data for Laboratorios Paill is sourced from the official FDA Data Dashboard (datadashboard.fda.gov), a public government database maintained by the U.S. Food and Drug Administration.

Data sourced from the FDA Data Dashboard, a public database maintained by the U.S. Food and Drug Administration.